Replies to post #154829 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Note that the (-) and (+) preceding A2-73 are significant in the understanding of this patent.

E.g.

F. "Classifying" cells as to the s 1 or 2 receptor populations shall mean determining the presence and or density of either s 1 or 2 receptors on cell surfaces in a given cell population. Classifying takes advantage of the differential populations of sigma receptors used as biomarkers. Biomarkers are useful as a means to define cell population propensities such as the likelihood of proliferation as to breast cancers. Testing methodology is more fully set forth in the following:

[nidan7500]

Example 5

Neuroprotection against amyloid

An 80 year old female patient is diagnosed with AD and treated with 10 mg of T Anevex2-73 substantially free of Anavex2-73 ® daily for 3 yrs. The patient's cognitive score stabilizes and then increases slowly and regularly over the following months.

Well now, is this an example of RWE?

[Amatuer17]

What this means?

“A pharmaceutical preparation comprising ©A2-73 substantially free of © A2-73”

[tredenwater2]

Investor/ Rocalinda sounds like a pretty "precise" type of patent to me. Hmmm, a precision patent to go along with our precision medicine company for numerous CNS diseases and cancer (listed). Im very surprised why our management hasnt started our precision medicine trials yet. My guess is they are STILL thinking 5 steps ahead of every yahoo on this board.

When the day comes that A 2-73 becomes approved as the SOC for the first of many diseases by reverse engineering/designing our drug through precision trials protected by precision patents I will promise not to tell those with no clue that "I told you so".

promise cross my heart!

Tred